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ABSTRAK
Oftalmopati Graves merupakan manifestasi ekstra-tiroid yang paling sering dijumpai pada pasien dengan 
penyakit Graves, yang didasari oleh kondisi inflamasi dan autoimun pada jaringan orbital. Panduan praktis 
ini dibuat oleh tim dengan anggota yang terdiri dari berbagai disiplin ilmu, dan diharapkan dapat memberikan 
panduan untuk pendekatan diagnosis dan tatalaksana oftalmopati Graves dalam praktek klinik sehari-hari untuk 
meningkatkan mutu pelayanan dan hasil pengobatan pada pasien.
Kata kunci: oftalmopati graves, diagnosis, tata laksana.
ABTRACT
Graves’ ophthalmopathy is the most common extra-thyroid manifestation in patients with Graves’ disease, 
based on inflammatory and autoimmune conditions in orbital tissue. This practical guideline was formed 
by a multidiciplinary team, and is intended to provide guidance for diagnosis and management of Graves’ 
ophthalmopathy in daily clinical practice to improve quality of care and treatment outcome.
Keywords: Graves’ ophthalmopathy, diagnosis, management.
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INTRODUCTION
Graves’ ophthalmopathy (GO) is one of the 
most common extra-thyroid manifestation of 
Graves’ disease. Clinically visible manifestation 
of GO can be observed in approximately 25-50% 
of patients with Graves’ disease.1 However, 
when computed-tomography (CT) scan or 
orbital magnetic resonance imaging (MRI) was 
performed, GO can be detected in almost 90% of 
the patients.2 According to Cipto Mangunkusumo 
National General Hospital, Jakarta, Indonesia 
in 2004, prevalence of Graves’ disease in all 
patients with thyroid symptoms was 21%. 
About 32% of which presented with clinically 
visible eye abnormalities.3 A study by Subekti 
et al. at Cipto Mangunkusumo National General 
Hospital, diagnosis of GO was made in 37.3% 
of patients coming to the hospital with clinical 
eye abnormalities and 83.6% of patients through 
orbital CT scans.4
In GO treatment, there is no guarantee 
that the eye abnormalities will improve along 
with the improvement of thyrotoxicosis. GO 
management was often not optimal because of the 
unstandardized parameters. Therefore, in order to 
achieve the desired treatment results, management 
of GO must include a comprehensive assessment 
of the clinical activity and severity of GO as well 
as the quality of life of patients.1
This practical guide is intended to provide 
guidance for primary care physicians/ doctors, 
specialists (internal medicine, eye, radiology, 
nuclear medicine, radiotherapy, surgery, etc.), 
specialist-consultants (endocrinology and 
metabolism consultants, eye consultants, radiology 
consultants, nuclear medicine consultants, etc.), 
and related healthcare providers in the diagnosis 
and management of GO in order to improve 
quality of care and treatment outcomes.
DEFINITION
Graves Ophthalmopathy (GO) is an 
inflammatory eye disease in the orbita, including 
its consequences, which are associated with 
autoimmune thyroid disease.5
PATHOGENESIS
Genetic, environmental, and endogenous 
factors can change the characteristic of the 
TSH receptor, which causes B lymphocytes to 
produce antibodies against the TSH receptor 
(TSHR-Ab). The TSHR-Ab binds to the TSH 
receptor which causes hyperthyroidism leading 
to thyrotoxicosis as well as thyroid follicle 
cell hyperplasia leading to the development of 
goitre. TSHR-Ab also binds to TSH receptor in 
adipocytes and orbital fibroblast, thus initiates 
the secretion of proinflammatory cytokines 
by T cells and glycosaminoglycans (GAG) by 
fibroblasts. Proinflammatory cytokines can cause 
fibrosis, while accumulation of GAG contributes 
to the increase of volume of extraocular muscle, 
connective tissue, and orbital adipocytes.
RISK FACTOR
Table 1 showed risk factors for GO based on 
the American Thyroid Association (ATA) 2016.5
Table 1. GO risk factor5
Risk factor Comments Amenable to intervention
Age Advanced age, have a higher risk for severe GO No
Gender GO is more frequent in women, but more severe in men No
Genetic Highest prevalence of GO in Caucasians, lowest in Asians. Immunomodulatory genes likely involved No
Mechanical factors Orbital lateral wall angle is wider in GO patients No
TSHR-Ab Predicts GO risk and treatment response No
Smoking Increases GO progression and decreases treatment efficacy Yes
Thyroid dysfunction Need for expeditious control of hyperthyroidism then prevention of hypothyroidism post graves disease therapy. Yes
Radioactive Iodine (RAI) 
therapy
Risk is additive to smoking; increased with preexistent and active GO; 
preventable by glucocorticoids 6–12 weeks post RAI. Yes




The diagnosis of GO is established by the 
presence of ocular signs and symptoms. The 
ocular symptoms of GO are gritty sensation in 
the eyes, pressure or pain in the eyes (30%), 
double vision (17%), lacrimation/ photophobia 
(15-20%), and blurred vision (7.5%). The 
ocular signs of GO are conjunctival and eyelid 
edema, proptosis or exophthalmus, eyelid 
retraction (>90%), lid lag (50%), restrictive 
extraocular myopathy (40%), and optic nerve 
dysfunction (5%). Other clinical features 
incluseds pretibial myxedema (4%), acropachy 
(1%), and myasthenia gravis (<1%). In Graves’ 
disease with typical eye abnormalities, diagnosis 
can be made without orbital imaging. Some 




Imaging modalities in GO are orbital CT 
scans and MRI. Orbital imaging is done to 
evaluate: (1) Non-characteristic/ asymmetrical 
eye abnormalities; (2) involvement/ compression 
of optic nerves; and (3) Orbital structures in 
preparation for decompression and rehabilitation 
surgeries. Orbital CT scan is not routinely 
performed in mild GO, unless there is complaint 
of diplopia or suspicion of other retroorbital 
abnormalities. Orbital imaging plays an 
important role in the differential diagnosis and 
interdisciplinary management of GO patients. 
Extraocular muscle thickening has been found 
through CT scan in mild GO (grade 0 in 
NOSPECS classification).2
CLASSIFICATION
GO classification is based on clinical activity 
score and degree of severity. Clinical activity 
and severity assessment are tools to choose the 
appropriate treatment options.
Clinical activity is clinical symptoms and 
signs that addresses the degree of inflammation. 
It is assessed using clinical activity score (CAS), 
which consists of active and inactive GO.
Degree of severity is clinical features of 
the eye associated with changes in anatomical 
structure, risk of sight-threatening GO, and 
quality of life. It is assessed using EuGOGO 
(European Group on Graves’ Orbitopathy) 
criteria, which consists of mild, moderate-to-
severe, and very severe GO. Assessment criteria 
can be seen in Table 2 and Table 3.
Data obtained from the NOSPECS 
examination is then used to determine the 
severity of GO based on EuGOGO criteria.
MANAGEMENT
Every GO patient needs to undergo a 
treatment program in order to achieve 
euthyroidism, smoking cessation, and local eye 
Table 2. GO clinical activity score (CAS)1
CAS first examination, point 1-7:
1. Spontaneous retrobulbar pain
2. Pain on attempted upward or downward gaze
3. Swelling of eyelids
4. Redness of eyelids
5. Redness of conjunctiva
6. Swelling of conjunctiva (chemosis)
7. Swelling of caruncle or plica
Monitoring after 1-3 months, point 8-10:
8. Increase in measured proptosis >2 mm
9. Decrease in eye movement limit of >8o any direction
10. Decrease in visual acuity equal to 1 Snellen chart line
Note:
*active GO = CAS ≥3/7 in fisrt examination or >4/10 on monitoring
*inactive GO = CAS <3/7 in first examination or ≤4/10 on monitoring
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care. Patients with mild GO that can be controlled 
with antithyroid drugs and local lubricants do 
not need to be referred to specialists. All GO 
patients with hyperthyroidism are treated to 
achieve euthyroidism by reducing either the 
synthesis of thyroid hormone through antithyroid 
drugs or the amount of thyroid tissue through 
radioactive iodine or total thyroidectomy. 
Patients with hyperthyroidism who get radioctive 
iodine treatment and show risk factors for GO 
or patients with mild active GO can be given 
glucocorticod prophylaxis.6
Approach in GO management includes 
non-pharmacological, pharmacological, 
rehabilitative surgery, and radiotherapy, based 
on the assessment of clinical activity and degree 
of severity (Figure 1).
Table 3. GO degree of severity with NOSPECS1
No signs or symptoms (degree of severity 0)
Only signs, no symptoms (degree of severity 1)
Lid aperture (distance between lid margins in mm with patient looking in primary position, sitting relaxed, with distant 
fixation)
Soft tissue involvement (degree of severity 2)
Swelling/redness of the eyes
Proptosis (degree of severity 3)
Exophthalmos (in mm: using the same Hertel exophthalmometer and same intercanthal distance for an individual 
patient)
Extraocular muscle involvement (degree of severity 4)
Eye muscle ductions in degrees; subjective diplopia score:
 - Intermittent (diplopia when tired or first awakening);
 - Inconstant (diplopia at extremes of gaze);
 - Constant (continuous diplopia in primary or reading position).
Corneal involvement (degree of severity 5)
Absent/ punctuate keratopathy, ulcer
Sight loss (optiv nerve involvement) (degree of severity 6)
Best-corrected visual acuity, color vision, optic disk, relative afferent papillary defect, visual fields (if optic nerve 
compression is suspected)
Table 4. Assessment of GO severity based on EuGOGO1
Mild GO
Mild GO manifestations have a minimum impact on the daily life. It usually appears in one or more of the following signs:
 - Minor lid retraction (<2 mm)
 - Mild soft-tissue involvement
 - Exophtalmos <3 mm above normal for race and gender (women 18 mm, men 20 mm)
 - No or intermittent diplopia 
 - Corneal exposure responsive to lubricants
Moderate-to-severe GO
Patients without sight-threatening GO with sufficient impact on the daily life, who need immunosuppression (if GO is 
active) or surgical intervention (if inactive). Two or more of the following sign usually appear:
 - Lid retraction (≥2 mm)
 - Moderate or severe soft-tissue involvement
 - Exophtalmos ≥3 mm above normal for race and gender (women 18 mm, men 20 mm)
 - Inconstant or constant diplopia
Very severe GO (sight-threatening)
Patients with dysthyroid optic neuropathy (DON) or sight-threatening corneal breakdown.
Rare cases: Eyeball subluxation, severe form of "frozen eye", choroidal folds, postural visual darkening.
Imam Subekti                                                                                                           Acta Med Indones-Indones J Intern Med
368
Topical Eye Care
Dry eyes are treated with preservative-free 
artificial tear eye drops with osmoprotective 
agents and long-acting analgesics. If needed, it 
can be used several times a day to protect the 
surface and epithelium of the eyes and to control 
eye symptoms in the early stage of the disease. 
In the later stage, gel or ointment can be used, 
especially at night.1,7 Elevating the head and and 
closing the eyes using eye-tape at night can help 
prevent nocturnal corneal dryness.8 Mild diplopia 
can be controlled with the use of prisms.8 In 
addition, protective googles can also be used to 
keep the eyes from foreign objects.
Pharmacological Therapy, Rehabilitative 
Surgery, and Radiotherapy
The choice of pharmacological therapy, 
rehabilitative surgery, and radiotherapy are based 
on clinical activity and degree of severity.
Glucocorticoids are the first choice on 
pharmacological therapy that can be given for 
clinically active GO. Glucocorticoids can be 
administered through oral, intravenous, or local 
route. Local administration of glucocorticoids 
through subconjunctival or retrobulbar injection 
is not recommended due to the risk of trauma 
and unproven effectiveness. Intravenous 
glucocorticoids have showed better response 
and improvement in clinical activity compared 
with oral administration. Some contraindications 
of methylprednisolone as part of GO therapy are 
(1) History of viral hepatitis (evidence of recent 
viral hepatitis); (2) Significant liver dysfunction; 
(3) Severe cardiovascular morbidity; (4) 
Uncontrolled hypertension; (5) Psychiatric 
disorders; and (6) Uncontrolled diabetes.8,9
Proton pump inhibitors can be administered 
along with glucocorticoids to prevent peptic 
ulcers, and bone protection may be required, 
especially in patients high-risk for osteoporosis.
Side effects of high-dose oral glucocorticoids 
include cataracts, peptic ulcer, prolonged 
suppression of adrenal function, Cushing’s 
syndrome, hypertension, diabetes, osteoporosis, 
reactivation of chronic disease (such as 
tuberculosis), infection, and psychosis.8
If intravenous glucocorticoid administration 
is not possible, oral prednisone can be given 
for 12 weeks, with initial dose of 0.2 gram/day, 
gradually tappered down to and 0.01 gram/week 
(cumulative dose of 4 grams).10,11
There  a re  severa l  a l t e rna t ives  to 
glucocorticoids that are extensively studied, 
such as rituximab, anti-interleukin-6 (IL-6) 
tocilizumab receptor, and anti-insulin growth 
factor 1 receptor (IGF-1R) teprotumumab.12 
Rituximab is a second-line therapy that can be 
given to moderate-to-severe active GO who 
fail the initial therapy or show glucocorticoids 
resistance.13 Tocilizumab is associated with 
ocular improvement, such as  increase in visual 
acuity and decrease in intraocular pressure.14 
* : Refer to specialists
** : Refer to endocrinology and 
metabolism or eye consultants
*** : Refer to eye consultants
# : If available.
Figure 1. Management of GO1
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Teprotumumab is a new immunosuppresive 
agents which can effectively reduce proptosis 
and improve clinical activity of GO.15
Mild GO
In mild GO, the focus is to give a topical eye 
protection and control of the risk factors. When 
the impact of GO on quality of life exceeds the 
risk of therapy, intravenous glucocorticoids as 
immunosuppressive agents can be given to active 
GO and rehabilitative surgery for inactive GO.
Treatment of mild GO begins with observation 
and, if available, twice-daily selenium 100 mg 
for 6 months in order to improve eye symptoms 
and quality of life, as well as to prevent the 
progression of GO. In a controlled clinical trial, 
no side effects of selenium were shown in GO. 
Selenium is less effective in mild chronic inactive 
GO, thus if needed, rehabilitative surgery is more 
recommended.1
Moderate-to-severe Active GO
High-dose systemic glucocorticoids are 
the first line of moderate-to-severe active GO. 
Intravenous glucocorticoids show 70-80% 
effectiveness, while oral administration only 
50%. In addition, intravenous glucocorticoids 
show better tolerance than oral.
Moderate-to-severe active GO management 
and steps after 4 weeks of treatment can be seen 
in Figure 2.1,7
Methylprednisolone is given as much as 500 
mg/day for 3 consecutive days, repeated every 
week for 4 weeks, so that the cumulative dose 
of 6 grams is obtained. Glucocorticoid therapy 
as first line is generally effective for moderate-
to-severe active GO.
If there is a partial or inadequate response 
to glucocorticoids, there are several therapeutic 
options:
1. Second course intravenous glucocorticoids 
if the patients show good tolerance in first 
course of glucocorticoids, but does not 
exceed 8 gram cumulative dose in the second 
course of administration
2. Combination of oral glucocorticoids and 
orbital radiotherapy
• Orbital radiotherapy shows potential to 
provide a synergistic effect along with 
oral glucocorticoids.
• Cumulative dose 20 Gy per eye divided 
into 10 daily doses given over a period 
of 2 weeks, or a dose of 1 Gy per week 
for a period of 20 weeks, which has the 
same effectiveness and better tolerance.1
• Mi ld  t rans ient  exacerbat ion  of 
ocular symptoms might occur and 
can be controlled with low-dose oral 
glucocorticoids.
• Contraindications to radiotherapy in 
GO are history of retinopathy and/or 
uncontrolled diabetes.
• Radiotherapy can be done using CT scan-
based technique, such as 3-dimensional 
conformal radiotherapy (3DCRT), 
intensity modulated radiotherapy 
Figure 2. Moderate-to-severe active GO treatment1
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(IMRT), or volumetric modulated arc 
radiotherapy (VMAT).
3. Combination of oral glucocorticoids and 
cyclosporine
• Prednisone 100 mg/day gradually 
tappered down for 3 months, given in 
single or combination with cyclosporine 
with initial dose of 5 mg/kg/day for 
12 months. Combination therapy is 
associated with better ocular outcome 
and lower rate of recurrence, or
• Prednisone with initial dose of 60 mg/day 
with/or cyclosporine with initial dose of 
7.5 mg/kg/day for 12 weeks. As many as 
60% of patients who did not respond to 
single therapy show better response to 
combination therapy.
4. Rituximab
• Rituximab 1,000 mg given twice in two 
weeks, or rituximab 100 mg followed by 
injection of 500 mg single dose.
• Side effects can be prevented by 
antihistamine premedication and 100 
mg hydrocortisone. Side effects of 
periorbital edema and inflammation can 
also occur.
5. Other therapies
• Periocular triamcinolone injection 20 
mg/week for 4 consecutive weeks show 
decrease in diplopia and the size of the 
extraocular muscle in newly active GO 
without local or systemic side effects.
• Subconjunctival triamcinolone injection 
is effective in reducing swelling and mild 
retraction of the eyelids in new onset of 
GO, with transient elevation in IOP.1
• If symptoms relapse after glucocorticoid 
doses tappered down or there is no 
clinical improvement after glucocorticoid 
administration, bromocriptine 1.25-
7.5 mg/day gradually increased can be 
considered for 3-10 months single or in 
with glucocorticoid.1–5
• Methotrexate is an alternative in case 
of glucocorticoid side effects, either 
7.5-15 mg/week orally or 20 mg by 
subcutaneous injection.7,8
Choice of therapy mentioned above can be 
considered as second-line therapy. However, the 
choice of therapy should be decided together in 
a multidisciplinary manner, taking into account 
the advantages and disadvantages for patients 
from various aspects.
Moderate-to-severe Inactive GO
Rehabilitative surgery is recommended in 
patients with GO who have significant altered 
visual function or quality of life after GO become 
inactive for at least 6 months. If more than one 
procedure of rehabilitative surgery is needed, the 
sequence of procedures is performed, namely 
decompression surgery, strabismus surgery, then 
periorbital and eyelids cosmetic surgery, since 
the prior procedure affect the latter.
a. Orbital decompression surgery. Orbital 
decompression surgery is indicated in severe 
and persistent proptosis, especially if there 
is an inadequate response to glucocorticoid 
therapy and or orbital radiotherapy and 
if there is keratitis, and optic neuropathy 
due to suppression of the optic nerve.8 
Decompression surgery aims to reduce 
intraocular pressure, reduce exophthalmus, 
eyelids retraction, pain, reduce strabismus, 
and improve blurred vision due to orbital 
microvasculopathy and optic nerve.
b. Strabismus surgery. Strabismus surgery aims 
to improve diplopia. This surgery is needed 
because extraocular muscle involvement 
often does not respond to drug therapy and 
worsens after orbital decompression surgery.
c. Periorbital and eyelids cosmetic surgery. 
This surgery aims to repair the eyelids. 
Retraction of the upper and lower eyelids 
is a combination of the inflammatory and 
fibrotic process, adrenergic stimulation, as 
well as vertical rectus muscle restriction. 
In addition, exophthalmus also increases 
eyelids aperture.
Very Severe GO
Very severe GO caused by dysthyroid optic 
neuropathy (DON) and or exposure to the cornea 
or corneal damage is an emergency that requires 
immediate treatment. Eyeball subluxation can 
occur through the traction of the optic nerve with/
without corneal damage.
First-line therapy in DON is intravenous 
g lucocor t i co ids ,  fo r  example  s ing le 
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methylprednisolone 500-1,000 mg for 3 
consecutive days or intervals a day for 1 week. If 
the response is not good or there is deterioration 
in visual function, decompression surgery needs 
to be performed.1
MONITORING
Initial response can predict a long-term 
response to glucocorticoid therapy. Things to 
consider in monitoring:
1. Glucocorticoids should not be used for more 
than 12 weeks with cumulative dose of 
methylprednisolone not exceeding 8 grams.
2. Blood glucose, liver function, and blood 
pressure should be controlled every month 
during therapy.
3. After cessation of glucocorticoids, it is 
necessary to monitor orbital vascular 
congestion that resembles active GO images, 
such as eyelid edema, eyelid or conjunctival 
redness, and chemosis, especially in patients 
with longer duration of illness.1,7
QUALITY OF LIFE ASSESSMENT
GO management should be done through a 
“centered” approach to patients, which includes 
the effects of the disease and therapeutic effects 
on quality of life and psychosocial aspects of the 
patient (Appendix 1).
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